UPDATE: Chardan Upgrades Esperion (ESPR) to Neutral But Maintains Negative Bias

Esperion Therapeutics (ESPR) 'Highly Oversold', Needham & Company Says

Needham & Company analyst Chad Messer reiterated a Buy rating and $115 price target on Esperion Therapeutics (NASDAQ: ESPR) as the company is pivoting back toward a dual track Phase III plan focused on approval in both statin-intolerant and statin add-on patients. The analyst views shares as... More

Esperion Therapeutics' (ESPR) Price Target Reduced to $105 at RBC

RBC Capital maintained an Outperform rating on Esperion Therapeutics (NASDAQ: ESPR) but lowered its price target to $105.00 (from $150.00). Yesterday Esperion provided investors with an updated on end of phase 2 FDA meeting minutes.

"We reduced our PT to $105 from $150 based on lowering... More

Esperion Therapeutics (ESPR) PT Lowered to $69 at UBS; 'Buy' Maintained

UBS analyst Andrew Peters slashed his price target on Esperion Therapeutics (NASDAQ: ESPR) to $69.00 (from $133.00) but maintained a Buy rating after the company announced updated development plans and timelines following the receipt of minutes from their end-of-ph2 meeting with FDA.

"Notably, while the update does not provide... More

Esperion (ESPR) Gives Update on ETC-1002's Phase 3 Following Receipt of FDA Meeting Minutes

Esperion Therapeutics, Inc. (NASDAQ: ESPR), a pharmaceutical company focused on developing and commercializing a first-in-class, oral therapy for low-density lipoprotein cholesterol (LDL-C) lowering for the treatment of patients with hypercholesterolemia, provided an update on the design and timing of its planned pivotal Phase 3 clinical development program following receipt of the official End-of-Phase 2 Meeting Minutes from the U.S. Food and Drug Administration (FDA).

Esperion plans to conduct multiple Phase 3 clinical trials that will separately evaluate patients with statin intolerance, as well as patients who are inadequately treated despite maximally tolerated statin therapy.... More